| (+)-Ochromycinone |
|
|
|
|
98.22% |
| (+)-Theta-cypermethrin |
|
|
|
|
|
| (14S,15R)-14-Deoxyoxacyclododecindione |
|
|
|
|
|
| (E/Z)-AG490 |
|
|
|
|
99.71% |
| (E/Z)-OSM-SMI-10B |
|
|
|
|
|
| (R)-α7 nAchR-JAK2-STAT3 agonist 1 |
|
|
|
|
99.59% |
| (R)-Lisofylline |
|
|
|
|
99.99% |
| (R,R)-VVD-118313 |
|
|
|
|
99.34% |
| (Rac)-8-Gingerol |
|
|
|
|
|
| (trans)-STAT6-IN-13 |
|
|
|
|
|
| 1-Stearoyl-sn-glycero-3-phosphocholine-d35 |
|
|
|
|
99% |
| 1-Stearoyl-sn-glycero-3-phosphocholine |
|
|
|
|
99.53% |
| 15(R)-Lipoxin A4 |
|
|
|
|
98.3% |
| 15-keto-Prostaglandin E2 |
|
|
|
|
99.0% |
| 2,4,5-Trimethoxybenzoic acid |
|
|
|
|
99.98% |
| 2-Chloro-5-(trifluoromethyl)pyrimidine |
|
|
|
|
99.84% |
| 2-NP |
|
|
|
|
99.55% |
| 2-Hydroxycinnamaldehyde |
|
|
|
|
99.86% |
| 3′,4′,7-Trihydroxyflavone |
|
|
|
|
99.04% |
| 3'-Demethylnobiletin |
|
|
|
|
99.98% |
| (E)-2-Hydroxycinnamaldehyde |
|
|
|
|
99.83% |
| 5,15-Diphenylporphyrin |
|
|
|
|
95.0% |
| 5,6,7-Trimethoxyflavone |
|
|
|
|
98.02% |
| 5-FAM-GpYLPQTV-NH2 |
|
|
|
|
99.45% |
| 5-FAM-GpYLPQTV-NH2 TFA |
|
|
|
|
98.17% |
| Leucrose |
|
|
|
|
98.53% |
| 6-Demethoxytangeretin |
|
|
|
|
99.37% |
| 7-epi-Isogarcinol |
|
|
|
|
|
| 8-Epixanthatin |
|
|
|
|
99.62% |
| 8-Gingerol |
|
|
|
|
99.82% |
| 8α-Tigloyloxyhirsutinolide 13-O-acetate |
|
|
|
|
95.0% |
| AC-4-130 |
|
|
|
|
99.93% |
| Ac-GpYLPQTV-NH2 |
|
|
|
|
|
| Ac-GpYLPQTV-NH2 acetate |
|
|
|
|
99.00% |
| ACHP |
|
|
|
|
|
| ADGRL1-IN-1 |
|
|
|
|
|
| AG490 |
|
|
|
|
99.86% |
| AH057 |
|
|
|
|
|
| AJI-100 |
|
|
|
|
|
| AJI-214 |
|
|
|
|
|
| AK-068 |
|
|
|
|
99.57% |
| AK-068-OH |
|
|
|
|
|
| AK-1690 |
|
|
|
|
99.17% |
| AK-2292 |
|
|
|
|
98.96% |
| AKR1B1/STAT3/SLC7A11-regulator-1 |
|
|
|
|
|
| ALK degrader 1 |
|
|
|
|
|
| ALOX5 stabilizer-1 |
|
|
|
|
|
| ALOX5 stabilizer-1 TFA |
|
|
|
|
|
| Angoline |
|
|
|
|
99.67% |
| Anthraquinone-2-carboxylic acid |
|
|
|
|
98.0% |
| Anti-IL11 Antibody (X203) |
|
|
|
|
98.53% |
| Anti-inflammatory agent 91 |
|
|
|
|
|
| Anti-inflammatory agent 92 |
|
|
|
|
|
| Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) |
|
|
|
|
95.00% |
| Anti-Mouse CD276/B7-H3 Antibody (MJ18) |
|
|
|
|
95.00% |
| Anti-Mouse IL-6 Antibody (MP5-20F3) |
|
|
|
|
99.36% |
| Anti-Mouse NK1.1 Antibody (PK136) |
|
|
|
|
98.57% |
| Anti-STAT3 Antibody |
|
|
|
|
|
| anti-TNBC agent-7 |
|
|
|
|
|
| Anticancer agent 259 |
|
|
|
|
|
| Antitumor agent-195 |
|
|
|
|
|
| Apoptosis inducer 55 |
|
|
|
|
|
| APT STAT3 |
|
|
|
|
99.38% |
| APT STAT3, scrambled |
|
|
|
|
|
| APTSTAT3-9R |
|
|
|
|
98.82% |
| APTSTAT3-9R, scrambled |
|
|
|
|
|
| AS1517499 |
|
|
|
|
98.99% |
| AS1810722 |
|
|
|
|
98.10% |
| AS2863619 |
|
|
|
|
98.02% |
| AS2863619 free base |
|
|
|
|
99.67% |
| Ascochlorin |
|
|
|
|
|
| ASP3026 |
|
|
|
|
99.88% |
| Atiprimod |
|
|
|
|
|
| Atiprimod dimaleate |
|
|
|
|
|
| Atiprimod hydrochloride |
|
|
|
|
|
| AUH-6-96 |
|
|
|
|
|
| Avatrombopag maleate |
|
|
|
|
99.99% |
| Avicin D |
|
|
|
|
|
| AX-202 |
|
|
|
|
98.91% |
| BAY-356 |
|
|
|
|
|
| BCI-137 |
|
|
|
|
99.84% |
| BD750 |
|
|
|
|
99.02% |
| Betavulgarin |
|
|
|
|
|
| Biflorin |
|
|
|
|
99.54% |
| BML-260 |
|
|
|
|
99.65% |
| BP-1-102 |
|
|
|
|
99.26% |
| BP-1-108 |
|
|
|
|
|
| BP79 |
|
|
|
|
|
| BRD4-IN-41 |
|
|
|
|
|
| Brevilin A |
|
|
|
|
99.86% |
| Broussonin E |
|
|
|
|
98.11% |
| Bruceantinol |
|
|
|
|
98.89% |
| Butamirate |
|
|
|
|
96.48% |
| Butamirate citrate |
|
|
|
|
99.88% |
| Butyzamide |
|
|
|
|
99.83% |
| Butyzamide |
|
|
|
|
|
| BVB808 |
|
|
|
|
|
| c-Met-IN-24 |
|
|
|
|
|
| C188 |
|
|
|
|
98.29% |
| C188-9 |
|
|
|
|
99.75% |
| Calenduloside E |
|
|
|
|
99.07% |
| Cappariloside A |
|
|
|
|
|
| CAY10526 |
|
|
|
|
99.12% |
| CAY10594 |
|
|
|
|
98.64% |
| CDK6/9-IN-2 |
|
|
|
|
|
| CDK8-IN-16 |
|
|
|
|
|
| CDK8-IN-2 |
|
|
|
|
|
| CDK8/19-IN-2 |
|
|
|
|
|
| Cenisertib |
|
|
|
|
99.86% |
| Cenisertib benzoate |
|
|
|
|
|
| Cernuumolide J |
|
|
|
|
|
| CHI3L1-IN-4 |
|
|
|
|
|
| CHI3L1-IN-6 |
|
|
|
|
|
| CHI3L1-IN-7 |
|
|
|
|
|
| CHMFL-48 |
|
|
|
|
|
| Cinnamtannin D1 |
|
|
|
|
|
| CMD178 |
|
|
|
|
|
| CMD178 TFA |
|
|
|
|
99.71% |
| Colivelin |
|
|
|
|
99.92% |
| Colivelin TFA |
|
|
|
|
99.79% |
| Corylifol A |
|
|
|
|
99.58% |
| CPA-7 |
|
|
|
|
|
| Crispene E |
|
|
|
|
|
| CSF1R-IN-26 |
|
|
|
|
|
| CT-1 |
|
|
|
|
99.90% |
| CT1113 |
|
|
|
|
99.61% |
| Cyanidin 3,5-diglucoside chloride |
|
|
|
|
99.44% |
| Cyanidin 3,5-diglucoside chloride (Standard) |
|
|
|
|
|
| Cyclanoline chloride |
|
|
|
|
96.27% |
| Cyclo(L-Ile-D-Leu) |
|
|
|
|
|
| CYD0682 |
|
|
|
|
|
| Danvatirsen |
|
|
|
|
99.12% |
| Danvatirsen sodium |
|
|
|
|
99.46% |
| Danvatirsen sodium scrambled negative control |
|
|
|
|
|
| DCZ3301 |
|
|
|
|
99.73% |
| Debio 0617B |
|
|
|
|
|
| Demethylasterriquinone B1 |
|
|
|
|
98.10% |
| DETD-35 |
|
|
|
|
|
| Deucravacitinib |
|
|
|
|
99.93% |
| Deucravacitinib hydrochloride |
|
|
|
|
|
| DG-8 |
|
|
|
|
|
| Dimethyl biphenyl-4,4'-dicarboxylate |
|
|
|
|
99.85% |
| DM243 |
|
|
|
|
|
| DM245 |
|
|
|
|
|
| DPP |
|
|
|
|
|
| DU-14 (PTP1B/TC-PTP PROTAC) |
|
|
|
|
99.78% |
| Dual Cathepsin L/JAK-IN-1 |
|
|
|
|
98.47% |
| DZ2002 |
|
|
|
|
99.83% |
| EC-70124 |
|
|
|
|
|
| Efbemalenograstim alfa |
|
|
|
|
97.68% |
| EGFR kinase-IN-8 |
|
|
|
|
|
| EGFR-IN-151 |
|
|
|
|
|
| EGFR-IN-173 |
|
|
|
|
|
| EGFR/STAT3-IN-1 |
|
|
|
|
|
| ENMD-1198 |
|
|
|
|
98.48% |
| ENT-03 |
|
|
|
|
|
| Equisetin |
|
|
|
|
99.40% |
| ER-464195-01 |
|
|
|
|
99.72% |
| Erasin |
|
|
|
|
96.02% |
| Eucannabinolide |
|
|
|
|
93.53% |
| Fa-Au |
|
|
|
|
|
| FAM-Danvatirsen |
|
|
|
|
|
| FLC-8 |
|
|
|
|
|
| FLLL32 |
|
|
|
|
99.41% |
| FLT3-IN-28 |
|
|
|
|
|
| FLT3-IN-32 hydrochloride |
|
|
|
|
|
| FLT3-IN-36 |
|
|
|
|
|
| FLT3-IN-37 |
|
|
|
|
|
| FLT3-IN-41 |
|
|
|
|
|
| FLT3/VEGFR2-IN-1 |
|
|
|
|
|
| Fraxinellone |
|
|
|
|
99.91% |
| Fulipiftide |
|
|
|
|
99.38% |
| Furowanin A |
|
|
|
|
|
| FYJ-195 |
|
|
|
|
|
| G721-0282 |
|
|
|
|
99.96% |
| Gamma-glutamylcysteine ammonium |
|
|
|
|
|
| Geranylgeranyl pyrophosphate |
|
|
|
|
|
| Geranylgeranyl pyrophosphate triammonium |
|
|
|
|
95.0% |
| Globulol |
|
|
|
|
99.74% |
| Glucocorticoid receptor/IL-6-IN-1 |
|
|
|
|
|
| GMB-475 |
|
|
|
|
98.69% |
| Golotimod |
|
|
|
|
98.04% |
| Golotimod hydrochloride |
|
|
|
|
99.64% |
| Golotimod TFA |
|
|
|
|
|
| GSK2618960 |
|
|
|
|
95.66% |
| GYY4137 |
|
|
|
|
98.64% |
| GYY4137 |
|
|
|
|
|
| GYY4137 (Standard) |
|
|
|
|
|
| HAT-SIL-TG-1&AT |
|
|
|
|
|
| HBS-101 |
|
|
|
|
99.59% |
| HD-2a |
|
|
|
|
|
| Heart-homing peptide |
|
|
|
|
|
| Hispidin |
|
|
|
|
99.85% |
| Histamine receptors inhibitor 1 |
|
|
|
|
|
| HJC0123 |
|
|
|
|
99.06% |
| HJC0149 |
|
|
|
|
|
| HJC0152 |
|
|
|
|
99.75% |
| HJC0152 free base |
|
|
|
|
|
| HJC0416 |
|
|
|
|
|
| HJC0416 hydrochloride |
|
|
|
|
98.68% |
| HO-3867 |
|
|
|
|
99.67% |
| HODHBt |
|
|
|
|
99.34% |
| HP590 |
|
|
|
|
98.02% |
| HSP110-IN-1 |
|
|
|
|
|
| Hsp110-STAT3 PPI-IN-1 |
|
|
|
|
|
| Hsp110-STAT3 PPI-IN-2 |
|
|
|
|
|
| Hsp110/HDAC6-IN-1 |
|
|
|
|
|
| Hydrazinocurcumin |
|
|
|
|
|
| HZ-1127 |
|
|
|
|
|
| I194496 |
|
|
|
|
98.52% |
| iBFAR2 |
|
|
|
|
97.24% |
| Ibrutinib-MPEA |
|
|
|
|
96.38% |
| Icariside I |
|
|
|
|
98.76% |
| Icotrokinra |
|
|
|
|
99.90% |
| Icotrokinra acetate |
|
|
|
|
|
| Icotrokinra hydrochloride |
|
|
|
|
99.74% |
| IFN-α Receptor Recognition Peptide 1 |
|
|
|
|
|
| IFN-α Receptor Recognition Peptide 1 acetate |
|
|
|
|
|
| iHSP110-33 |
|
|
|
|
99.59% |
| iJak-381 |
|
|
|
|
99.86% |
| IM-12 |
|
|
|
|
|
| IMC-EB10 |
|
|
|
|
98% |
| Iminostilbene-d10 |
|
|
|
|
|
| INCA033989 |
|
|
|
|
98.12% |
| INCB16562 |
|
|
|
|
|
| inS3-54-A26 |
|
|
|
|
|
| inS3-54A18 |
|
|
|
|
99.93% |
| IRAK4 modulator-2 |
|
|
|
|
99.86% |
| Iridin |
|
|
|
|
99.72% |
| Iruplinalkib |
|
|
|
|
99.62% |
| Isocryptotanshinone |
|
|
|
|
98% |
| Isocucurbitacin B |
|
|
|
|
98.98% |
| Isolinderalactone |
|
|
|
|
98.79% |
| IST5-002 |
|
|
|
|
99.83% |
| ITA-5 |
|
|
|
|
|
| ITA-9 |
|
|
|
|
|
| Itacitinib |
|
|
|
|
99.97% |
| Itacitinib adipate |
|
|
|
|
99.18% |
| Itacnosertib |
|
|
|
|
99.06% |
| Itacnosertib hydrochloride |
|
|
|
|
99.43% |
| JAK-IN-23 |
|
|
|
|
98.88% |
| JAK-IN-40 |
|
|
|
|
|
| JAK-STAT-IN-1 |
|
|
|
|
|
| JAK1-IN-16 |
|
|
|
|
|
| JAK1-IN-20 |
|
|
|
|
|
| JAK1/STAT3-IN-1 |
|
|
|
|
|
| JAK2-IN-10 |
|
|
|
|
97.97% |
| JAK2-IN-13 |
|
|
|
|
|
| JAK2-IN-14 |
|
|
|
|
|
| JAK2-IN-15 |
|
|
|
|
|
| JAK2-IN-18 |
|
|
|
|
|
| JAK2-IN-21 |
|
|
|
|
|
| JAK2-IN-9 |
|
|
|
|
|
| JAK2/STAT3-IN-2 |
|
|
|
|
|
| JAK3-IN-20 |
|
|
|
|
|
| JI069 |
|
|
|
|
98.03% |
| JMJD1C-IN-1 |
|
|
|
|
99.96% |
| JMS-053 |
|
|
|
|
98.0% |
| K882 |
|
|
|
|
|
| KB-0118 |
|
|
|
|
|
| KB-15 |
|
|
|
|
|
| KMR-206 |
|
|
|
|
98.86% |
| KSI-028 |
|
|
|
|
|
| KT-333 |
|
|
|
|
98.91% |
| KT-333 ammonium |
|
|
|
|
99.48% |
| KT-333 diammonium |
|
|
|
|
|
| KW-2478 |
|
|
|
|
99.53% |
| KW-2478 hydrochloride |
|
|
|
|
|
| L-Glutamine |
|
|
|
|
|
| L-Glutamine-1-13C |
|
|
|
|
98.0% |
| L-Glutamine-15N |
|
|
|
|
99.6% |
| L-Glutamine-15N-1 |
|
|
|
|
98.0% |
| L-Glutamine-15N2 |
|
|
|
|
99.95% |
| L-Glutamine-15N2,d5 |
|
|
|
|
|
| L-Glutamine-5-13C |
|
|
|
|
98.0% |
| L-Glutamine-d5 |
|
|
|
|
99.79% |
| L-Glutamine-13C5 |
|
|
|
|
99.93% |
| L-Glutamine-13C5,15N2 |
|
|
|
|
98.0% |
| L-Glutamine-13C5,15N2,d5 |
|
|
|
|
99.95% |
| L002 |
|
|
|
|
99.44% |
| LCC-12 formate |
|
|
|
|
99.90% |
| Liensinine perchlorate |
|
|
|
|
99.67% |
| LL-K8-22 |
|
|
|
|
99.06% |
| LLL12 |
|
|
|
|
99.45% |
| LLL3 |
|
|
|
|
97.20% |
| LNK01004 |
|
|
|
|
|
| Lorpucitinib |
|
|
|
|
99.95% |
| LRRK2 inhibitor 1 |
|
|
|
|
99.80% |
| Lss-11 |
|
|
|
|
|
| LWY713 |
|
|
|
|
|
| LY5 |
|
|
|
|
97.02% |
| MA191 |
|
|
|
|
|
| Madindoline A |
|
|
|
|
|
| MC0704 |
|
|
|
|
98.34% |
| MEAP |
|
|
|
|
|
| Methyllinderone |
|
|
|
|
|
| MG-3C |
|
|
|
|
|
| Minecoside |
|
|
|
|
99.86% |
| Mito-Esculetin |
|
|
|
|
|
| ML115 |
|
|
|
|
99.98% |
| MLS-2384 free base |
|
|
|
|
|
| MM-206 |
|
|
|
|
99.9% |
| MMP-2/9-IN-2 |
|
|
|
|
|
| MMPP |
|
|
|
|
98.06% |
| MNK8 |
|
|
|
|
99.76% |
| Mocravimod |
|
|
|
|
98.39% |
| Mocravimod hydrochloride |
|
|
|
|
99.99% |
| Momordicine I |
|
|
|
|
97.0% |
| MPT0B098 |
|
|
|
|
|
| MRC-G-001 |
|
|
|
|
|
| mTOR-IN-29 |
|
|
|
|
|
| mTOR/STAT3-IN-1 |
|
|
|
|
|
| Mulberrofuran G |
|
|
|
|
97.86% |
| N-Deacetyl-SI-109-(OEt)2 |
|
|
|
|
|
| Napabucasin |
|
|
|
|
99.94% |
| NF-κB-IN-19 |
|
|
|
|
|
| Niclosamide |
|
|
|
|
|
| Niclosamide olamine |
|
|
|
|
98.66% |
| Niclosamide-d3 |
|
|
|
|
|
| Nitroaspirin |
|
|
|
|
98.57% |
| Norbergenin |
|
|
|
|
98.31% |
| Notoginsenoside R4 |
|
|
|
|
99.34% |
| NSC 74859 |
|
|
|
|
98.35% |
| NSC 850745 |
|
|
|
|
|
| NSC-368262 |
|
|
|
|
|
| NSC-370284 |
|
|
|
|
99.27% |
| NT157 |
|
|
|
|
99.38% |
| NT219 |
|
|
|
|
98.57% |
| NTZ-24 |
|
|
|
|
|
| NVP-BVB808 |
|
|
|
|
|
| NW16 |
|
|
|
|
|
| Ochromycinone |
|
|
|
|
99.61% |
| ODZ10117 |
|
|
|
|
|
| Officinalisinin I |
|
|
|
|
99.80% |
| OK2 |
|
|
|
|
99.13% |
| Orazipone |
|
|
|
|
|
| ortho-Topolin riboside |
|
|
|
|
|
| OSM-SMI-10B |
|
|
|
|
99.70% |
| Osunprotafib |
|
|
|
|
99.38% |
| P-gp-IN-36 |
|
|
|
|
|
| Pabgraminone C |
|
|
|
|
|
| Paeoniflorin-6′-O-benzene sulfonate |
|
|
|
|
|
| Patiromer |
|
|
|
|
95.0% |
| PD-305 |
|
|
|
|
|
| PD-L1-IN-6 |
|
|
|
|
|
| PDGFRA/CAIX/XII-IN-1 |
|
|
|
|
98.10% |
| Pentadecanoic acid |
|
|
|
|
99.92% |
| Peruvoside |
|
|
|
|
99.32% |
| PF-06263276 |
|
|
|
|
98.26% |
| PF15 |
|
|
|
|
|
| PF15 TFA |
|
|
|
|
99.72% |
| Pheophytin a |
|
|
|
|
80.0% |
| PHI-501 |
|
|
|
|
|
| phospho-STAT3-IN-2 |
|
|
|
|
|
| Physalin A |
|
|
|
|
99.63% |
| Physalin D |
|
|
|
|
98.21% |
| PI3K/Akt/mTOR-IN-5 |
|
|
|
|
|
| PI3K/Akt/mTOR-IN-7 |
|
|
|
|
|
| PKM2 activator 11 |
|
|
|
|
|
| Plumericin |
|
|
|
|
|
| PM-43I |
|
|
|
|
98.87% |
| PM-81I |
|
|
|
|
99.91% |
| PMMB-187 |
|
|
|
|
|
| Poloxipan |
|
|
|
|
|
| Pomstafib-2 |
|
|
|
|
99.37% |
| pro-FTY |
|
|
|
|
|
| Prohibitin ligand 1 |
|
|
|
|
|
| PROTAC ALK degrader-4 |
|
|
|
|
|
| PROTAC ALK degrader-5 |
|
|
|
|
|
| PROTAC c-Met degrader-5 |
|
|
|
|
|
| PROTAC FLT-3 degrader 1 |
|
|
|
|
98.26% |
| PROTAC FLT3/CHK1 Degrader-1 |
|
|
|
|
|
| PROTAC JAK1 degrader 1 |
|
|
|
|
99.97% |
| PROTAC JAK1/2 degrader-1 |
|
|
|
|
99.47% |
| PROTAC JAK2 degrader-1 |
|
|
|
|
|
| PROTAC RET Degrader 2 |
|
|
|
|
|
| PROTAC SKP2 Degrader-1 |
|
|
|
|
99.91% |
| PROTAC STAT3 degrader-2 |
|
|
|
|
|
| PROTAC STAT3 degrader-3 |
|
|
|
|
99.75% |
| PROTAC STAT6 degrader-1 |
|
|
|
|
99.55% |
| PROTAC STAT6 degrader-10 |
|
|
|
|
|
| PROTAC STAT6 degrader-2 |
|
|
|
|
|
| PROTAC STAT6 degrader-3 |
|
|
|
|
98.66% |
| PROTAC STAT6 degrader-4 |
|
|
|
|
|
| PROTAC STAT6 degrader-5 |
|
|
|
|
|
| PROTAC STAT6 degrader-7 |
|
|
|
|
|
| PROTAC STAT6 degrader-8 |
|
|
|
|
|
| PROTAC STAT6 degrader-9 |
|
|
|
|
|
| PROTAC TYK2 degrader-1 |
|
|
|
|
99.46% |
| PTPN2-IN-2 |
|
|
|
|
|
| PTPN2/1-IN-4 |
|
|
|
|
|
| PVD-06 |
|
|
|
|
|
| QL-1200186 |
|
|
|
|
99.95% |
| Quinalizarin |
|
|
|
|
97.23% |
| Rafutrombopag |
|
|
|
|
95.29% |
| RBN012811 |
|
|
|
|
98.79% |
| Ritlecitinib |
|
|
|
|
99.63% |
| Ritlecitinib malonate |
|
|
|
|
|
| Ritlecitinib tosylate |
|
|
|
|
99.65% |
| Rivularin |
|
|
|
|
98.13% |
| RO8191 |
|
|
|
|
98.80% |
| ROCK2-IN-10 |
|
|
|
|
|
| ROCK2-IN-12 |
|
|
|
|
98.02% |
| ROCK2-IN-17 |
|
|
|
|
|
| ROCK2-IN-7 |
|
|
|
|
|
| RSVA405 |
|
|
|
|
99.72% |
| S-72 |
|
|
|
|
|
| S-Propargylcysteine |
|
|
|
|
97.0% |
| S1H |
|
|
|
|
99.32% |
| S3D5 |
|
|
|
|
|
| S3I-1757 |
|
|
|
|
99.51% |
| Salviolone |
|
|
|
|
99.32% |
| SB02024 |
|
|
|
|
99.70% |
| SBT-100 (His Tag) |
|
|
|
|
|
| SC-2001 |
|
|
|
|
99.37% |
| SC-43 |
|
|
|
|
99.01% |
| SC-60 |
|
|
|
|
|
| SC99 |
|
|
|
|
98.90% |
| SD-1008 |
|
|
|
|
99.10% |
| SD-1029 |
|
|
|
|
88.8% |
| SD-2301 |
|
|
|
|
|
| SD-36 |
|
|
|
|
99.73% |
| SD-436 |
|
|
|
|
98.27% |
| SD-91 |
|
|
|
|
97.49% |
| SD-965 |
|
|
|
|
|
| SH-4-54 |
|
|
|
|
99.80% |
| SH5-07 |
|
|
|
|
98.0% |
| SHP1 activator 1 |
|
|
|
|
99.38% |
| SHP2 inhibitor LY6 |
|
|
|
|
|
| SI-109 |
|
|
|
|
98.96% |
| SI-191 |
|
|
|
|
|
| SIRT5-IN-10 |
|
|
|
|
|
| SM-17 |
|
|
|
|
96.98% |
| Sm4 |
|
|
|
|
99.01% |
| SMI-10B13 |
|
|
|
|
99.30% |
| Stafia-1 |
|
|
|
|
99.39% |
| Stafia-1-dipivaloyloxymethyl ester |
|
|
|
|
95.38% |
| Stafib-1 |
|
|
|
|
99.25% |
| Stafib-2 |
|
|
|
|
99.97% |
| STAT-3/c-Src-IN-1 |
|
|
|
|
|
| STAT1/3-IN-1 |
|
|
|
|
99.23% |
| STAT3 degrader-1 |
|
|
|
|
|
| STAT3 HiBiT degrader 1 |
|
|
|
|
|
| STAT3 Human Pre-designed siRNA Set A |
|
|
|
|
|
| STAT3 ligand 5 |
|
|
|
|
|
| Stat3 Rat Pre-designed siRNA Set A |
|
|
|
|
|
| STAT3-D11-PROTAC-VHL |
|
|
|
|
96.33% |
| STAT3-IN-1 |
|
|
|
|
96.28% |
| STAT3-IN-10 |
|
|
|
|
|
| STAT3-IN-11 |
|
|
|
|
98.29% |
| STAT3-IN-12 |
|
|
|
|
99.87% |
| STAT3-IN-13 |
|
|
|
|
99.24% |
| STAT3-IN-14 |
|
|
|
|
95.89% |
| STAT3-IN-15 |
|
|
|
|
98.99% |
| STAT3-IN-17 |
|
|
|
|
98.0% |
| STAT3-IN-18 |
|
|
|
|
|
| STAT3-IN-20 |
|
|
|
|
99.83% |
| STAT3-IN-21, cell-permeable, negative control |
|
|
|
|
|
| STAT3-IN-23 |
|
|
|
|
|
| STAT3-IN-24, cell-permeable |
|
|
|
|
98.34% |
| STAT3-IN-25 |
|
|
|
|
99.36% |
| STAT3-IN-27 |
|
|
|
|
|
| STAT3-IN-28 |
|
|
|
|
|
| STAT3-IN-29 |
|
|
|
|
|
| STAT3-IN-3 |
|
|
|
|
98.40% |
| STAT3-IN-30 |
|
|
|
|
|
| STAT3-IN-31 |
|
|
|
|
99.70% |
| STAT3-IN-32 |
|
|
|
|
|
| STAT3-IN-33 |
|
|
|
|
|
| STAT3-IN-34 |
|
|
|
|
|
| STAT3-IN-35 |
|
|
|
|
|
| STAT3-IN-36 |
|
|
|
|
|
| STAT3-IN-37 |
|
|
|
|
|
| STAT3-IN-38 |
|
|
|
|
|
| STAT3-IN-39 |
|
|
|
|
|
| STAT3-IN-4 |
|
|
|
|
|
| STAT3-IN-40 |
|
|
|
|
|
| STAT3-IN-41 |
|
|
|
|
|
| STAT3-IN-43 |
|
|
|
|
|
| STAT3-IN-44 |
|
|
|
|
|
| STAT3-IN-46 |
|
|
|
|
|
| STAT3-IN-47 |
|
|
|
|
|
| STAT3-IN-48 |
|
|
|
|
98.64% |
| STAT3-IN-49 |
|
|
|
|
|
| STAT3-IN-5 |
|
|
|
|
|
| STAT3-IN-50 |
|
|
|
|
|
| STAT3-IN-51 |
|
|
|
|
|
| STAT3-IN-52 |
|
|
|
|
|
| STAT3-IN-53 |
|
|
|
|
|
| STAT3-IN-7 |
|
|
|
|
|
| STAT3-IN-8 |
|
|
|
|
|
| STAT3-IN-9 |
|
|
|
|
|
| STAT3-SH2 domain inhibitor 1 |
|
|
|
|
98.58% |
| STAT3/AKT-IN-1 |
|
|
|
|
|
| STAT3/CAIX-IN-1 |
|
|
|
|
|
| STAT3/HDAC-IN-2 |
|
|
|
|
|
| STAT3/NF-κB-IN-1 |
|
|
|
|
|
| STAT4-IN-1 |
|
|
|
|
99.17% |
| STAT5-IN-1 |
|
|
|
|
98.35% |
| STAT5-IN-2 |
|
|
|
|
98.90% |
| STAT5-IN-3 |
|
|
|
|
|
| STAT5B Human Pre-designed siRNA Set A |
|
|
|
|
|
| STAT6 degrader-1 |
|
|
|
|
|
| STAT6 degrader-3 |
|
|
|
|
99.26% |
| STAT6 degrader-4 |
|
|
|
|
|
| STAT6 Human Pre-designed siRNA Set A |
|
|
|
|
|
| STAT6 ligand-1 |
|
|
|
|
98.94% |
| STAT6 ligand-2 |
|
|
|
|
|
| STAT6 modulator-3 |
|
|
|
|
|
| Stat6 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
| STAT6-IN-1 |
|
|
|
|
99.81% |
| STAT6-IN-10 |
|
|
|
|
98.81% |
| STAT6-IN-11 |
|
|
|
|
|
| STAT6-IN-12 |
|
|
|
|
|
| STAT6-IN-13 |
|
|
|
|
|
| STAT6-IN-2 |
|
|
|
|
98.10% |
| STAT6-IN-3 |
|
|
|
|
99.97% |
| STAT6-IN-4 |
|
|
|
|
99.77% |
| STAT6-IN-5 |
|
|
|
|
99.88% |
| STAT6-IN-6 |
|
|
|
|
|
| STAT6-IN-7 |
|
|
|
|
99.53% |
| STAT6-IN-8 |
|
|
|
|
|
| STAT6-IN-9 |
|
|
|
|
98.11% |
| Stattic |
|
|
|
|
99.58% |
| STX-0119 |
|
|
|
|
98.40% |
| TAT-N15 |
|
|
|
|
|
| TAVO101 |
|
|
|
|
|
| TC-2559 free base |
|
|
|
|
|
| TDP-665759 |
|
|
|
|
|
| Thienodolin |
|
|
|
|
|
| TM-233 |
|
|
|
|
|
| TP-5801 |
|
|
|
|
98.55% |
| TP-5801 TFA |
|
|
|
|
99.55% |
| TPCA-1 |
|
|
|
|
98.75% |
| TPST2-IN-1 |
|
|
|
|
|
| Tricarbonyldichlororuthenium(II) dimer |
|
|
|
|
98.0% |
| TS-IN-5 |
|
|
|
|
|
| TU-100 |
|
|
|
|
|
| TYD-68 |
|
|
|
|
99.54% |
| Tyk2-IN-22-d3 |
|
|
|
|
|
| Tyk2-IN-23 |
|
|
|
|
|
| UC-514321 |
|
|
|
|
98.0% |
| UNC1062 |
|
|
|
|
98.92% |
| UNC1666 |
|
|
|
|
|
| Vanicoside B |
|
|
|
|
99.82% |
| VEGFR-2/STAT-3-IN-1 |
|
|
|
|
|
| VS-II-173 |
|
|
|
|
|
| VS-IP1 |
|
|
|
|
|
| VS1150 |
|
|
|
|
|
| VVD-118313 |
|
|
|
|
99.47% |
| W1131 |
|
|
|
|
99.45% |
| W1131 TFA |
|
|
|
|
99.27% |
| WB436B |
|
|
|
|
99.93% |
| WB518 |
|
|
|
|
96.48% |
| WCY-8-67 |
|
|
|
|
|
| WCY-8-67 TFA |
|
|
|
|
99.40% |
| Withaphysalin A |
|
|
|
|
98% |
| WP-1034 |
|
|
|
|
|
| WP1066 |
|
|
|
|
99.53% |
| WP1193 |
|
|
|
|
|
| WR-S-462 |
|
|
|
|
|
| WWQ-03-012 |
|
|
|
|
98.04% |
| WYE-151650 |
|
|
|
|
|
| WZ-2-033 |
|
|
|
|
|
| XD2-149 |
|
|
|
|
|
| XL-20 |
|
|
|
|
|
| XMU-MP-2 |
|
|
|
|
99.29% |
| XOMA-213 |
|
|
|
|
98.46% |
| XZH-5 |
|
|
|
|
|
| YLL545 |
|
|
|
|
|
| YM-341619 |
|
|
|
|
98.01% |
| YMU1 |
|
|
|
|
99.19% |
| YN11 |
|
|
|
|
|
| YSY01A |
|
|
|
|
|
| YYSW001 |
|
|
|
|
|
| YZ-35 |
|
|
|
|
|
| Z169667518 |
|
|
|
|
|
| ZDZ-553 |
|
|
|
|
|
| Zharp1-211 |
|
|
|
|
99.15% |
| Zingiberen newsaponin |
|
|
|
|
99.68% |
| Zn-DPA-maytansinoid conjugate 1 |
|
|
|
|
|
| α7 nAchR-JAK2-STAT3 agonist 1 |
|
|
|
|
98.51% |
| β-Funaltrexamine |
|
|
|
|
|
| β-Funaltrexamine hydrochloride |
|
|
|
|
99.07% |
| Gamma-glutamylcysteine |
|
|
|
|
98.53% |
| Gamma-glutamylcysteine TFA |
|
|
|
|
96.68% |
| Notoginsenoside R2 |
|
|
|
|
99.80% |
| Triacetylresveratrol |
|
|
|
|
99.11% |
| Rademikibart |
|
|
|
|
99.13% |
| Ethanolamine-d7 |
|
|
|
|
98.93% |
| Ethanolamine |
|
|
|
|
99.98% |
| Diminazene |
|
|
|
|
|
| Iminostilbene |
|
|
|
|
99.34% |
| Panaxadiol |
|
|
|
|
99.89% |
| Curculigoside |
|
|
|
|
99.82% |
| Garcinone C |
|
|
|
|
99.51% |
| Garcinone D |
|
|
|
|
99.30% |
| Clifutinib |
|
|
|
|
99.59% |
| Hexachlorobenzene |
|
|
|
|
98.82% |
| Ponicidin |
|
|
|
|
99.93% |
| Pimozide |
|
|
|
|
99.94% |
| Pimozide-d4 |
|
|
|
|
98.0% |
| Pimozide-d5 N-Oxide |
|
|
|
|
|
| Pimozide-d4-1 |
|
|
|
|
|
| Protosappanin A |
|
|
|
|
99.95% |
| Desmethoxyyangonin |
|
|
|
|
99.00% |
| Stapokibart |
|
|
|
|
99.37% |
| Pimozide-d5 |
|
|
|
|
|
| Fluacrypyrim |
|
|
|
|
97.49% |
| Tetramethylcurcumin |
|
|
|
|
99.91% |
| Alantolactone |
|
|
|
|
99.94% |
| Perindopril |
|
|
|
|
99.85% |
| Perindopril-d5 |
|
|
|
|
|
| Perindopril erbumine |
|
|
|
|
99.98% |
| Perindopril-d3 erbumine |
|
|
|
|
|
| Olokizumab |
|
|
|
|
99.54% |
| Anumigilimab |
|
|
|
|
98.43% |
| Microhelenin C |
|
|
|
|
99.55% |
| Arnicolide D |
|
|
|
|
99.69% |
| Balsalazide-d3 |
|
|
|
|
|
| Balsalazide-d4 |
|
|
|
|
99.9% |
| Balsalazide |
|
|
|
|
98.65% |
| Balsalazide disodium |
|
|
|
|
|
| Balsalazide sodium hydrate |
|
|
|
|
98.30% |
| Peramivir |
|
|
|
|
99.94% |
| Peramivir trihydrate |
|
|
|
|
98.30% |
| Isoscopoletin |
|
|
|
|
99.92% |
| Isotoosendanin |
|
|
|
|
99.51% |
| Serplulimab |
|
|
|
|
99.30% |
| Eflepedocokin alfa |
|
|
|
|
≥99.0% |
| Lestaurtinib |
|
|
|
|
99.66% |
| Tectochrysin |
|
|
|
|
99.82% |
| Saikosaponin B1 |
|
|
|
|
99.42% |
| Saikosaponin D |
|
|
|
|
99.81% |
| Phlorizin |
|
|
|
|
99.93% |
| Phlorizin dihydrate |
|
|
|
|
98.0% |
| Gliquidone |
|
|
|
|
99.93% |
| Morusin |
|
|
|
|
99.54% |
| Flurbiprofen axetil |
|
|
|
|
99.34% |
| Flubendazole |
|
|
|
|
99.05% |
| Fludarabine |
|
|
|
|
99.73% |
| Nitidine chloride |
|
|
|
|
99.82% |
| Delphinidin chloride |
|
|
|
|
98.0% |
| Niclosamide-13C6 |
|
|
|
|
99.0% |
| Niclosamide |
|
|
|
|
99.96% |
| Niclosamide monohydrate |
|
|
|
|
|
| Niclosamide-13C6 monohydrate |
|
|
|
|
|
| Niclosamide sodium |
|
|
|
|
|
| Sarilumab |
|
|
|
|
99.36% |
| Alisol F |
|
|
|
|
99.89% |
| Rafutrombopag (tautomerism) |
|
|
|
|
98.33% |
| Bromisoval |
|
|
|
|
99.81% |
| Cycloartenyl ferulate |
|
|
|
|
99.15% |
| Cycloguanil |
|
|
|
|
|
| Cycloguanil-d6 |
|
|
|
|
98.0% |
| Cycloguanil-d6 nitrate |
|
|
|
|
|
| Cycloguanil hydrochloride |
|
|
|
|
99.93% |
| Cycloguanil-d4 (hydrochloride) |
|
|
|
|
|
| Cycloguanil-d6 (hydrochloride) |
|
|
|
|
|
| Phellopterin |
|
|
|
|
99.94% |
| Glycodeoxycholic acid-d5 |
|
|
|
|
|
| Glycodeoxycholic acid |
|
|
|
|
99.91% |
| Glycochenodeoxycholic acid sodium salt |
|
|
|
|
98.51% |
| Kansuinine B |
|
|
|
|
99.0% |
| Glycochenodeoxycholic acid |
|
|
|
|
99.81% |
| Cirsilineol |
|
|
|
|
98.0% |
| Medrysone |
|
|
|
|
99.79% |
| Sorafenib tosylate |
|
|
|
|
99.98% |
| Reticuline |
|
|
|
|
98.89% |
| Pulchinenoside E2 |
|
|
|
|
99.28% |
| Byakangelicol |
|
|
|
|
98.66% |
| Atractylenolide I |
|
|
|
|
99.98% |
| Atractylenolide II |
|
|
|
|
99.89% |
| Atractylenolide II (Standard) |
|
|
|
|
|
| Phellodendrine chloride |
|
|
|
|
99.68% |
| Nifuratel |
|
|
|
|
99.93% |
| Nifuroxazide-d4 |
|
|
|
|
|
| Nifuroxazide-13C6 |
|
|
|
|
|
| Nifuroxazide |
|
|
|
|
99.90% |
| Sorafenib |
|
|
|
|
99.84% |
| Corynoline |
|
|
|
|
98.84% |
| Viridicatol |
|
|
|
|
99.93% |
| (-)-Asarinin |
|
|
|
|
99.90% |
| Mogrol |
|
|
|
|
99.76% |
| Galiellalactone |
|
|
|
|
|
| Picroside I |
|
|
|
|
99.31% |
| Graveoline |
|
|
|
|
99.93% |
| Sotetsuflavone |
|
|
|
|
|
| Atranorin |
|
|
|
|
99.68% |
| Liensinine |
|
|
|
|
99.97% |
| Liensinine Diperchlorate |
|
|
|
|
99.96% |
| Cucurbitacin I |
|
|
|
|
99.60% |
| Cucurbitacin IIa |
|
|
|
|
99.90% |
| Casticin |
|
|
|
|
99.68% |
| Diosgenin |
|
|
|
|
99.92% |
| Prosapogenin A |
|
|
|
|
99.88% |
| Astaxanthin |
|
|
|
|
98.0% |
| Bufothionine |
|
|
|
|
|
| Corylin |
|
|
|
|
99.97% |
| Cilengitide |
|
|
|
|
99.91% |
| Raspberry ketone glucoside |
|
|
|
|
99.52% |
| Cardamonin |
|
|
|
|
99.80% |
| Ergosterol peroxide |
|
|
|
|
99.57% |
| Telocinobufagin |
|
|
|
|
99.50% |
| Polygalaxanthone III |
|
|
|
|
99.28% |
| Physalin B |
|
|
|
|
97.20% |
| Eupalinolide K |
|
|
|
|
99.20% |
| Scutellarin |
|
|
|
|
99.57% |
| Ginkgolic acid C17:1 |
|
|
|
|
99.80% |
| Cryptotanshinone |
|
|
|
|
99.07% |
| Wilforine |
|
|
|
|
99.47% |
| Radotinib |
|
|
|
|
99.19% |
| Radotinib-d6 |
|
|
|
|
|
| Radotinib dihydrochloride |
|
|
|
|
|
| Artesunate-d3 |
|
|
|
|
|
| Artesunate-d4 |
|
|
|
|
|
| Artesunate |
|
|
|
|
99.89% |
| Fezakinumab |
|
|
|
|
99.9% |
| Gondoic acid |
|
|
|
|
95.0% |
| Homoharringtonine |
|
|
|
|
99.75% |
| Guanosine 5'-diphosphate |
|
|
|
|
|
| Guanosine 5'-diphosphate sodium, 96% (HPLC) |
|
|
|
|
99.88% |
| Phellodendrine |
|
|
|
|
|
| Bellidifolin |
|
|
|
|
99.74% |